Eversept Partners’s Whitehawk Therapeutics WHWK Stock Holding History

Eversept Partners’s Portfolio WHWK Stock Details WHWK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.39M	Sell	303,306 -3,494	-1%	-$14.5K	0.07%	99
2026 Q1	$1.06M	Buy	306,800 +46,541	+18%	+$146K	0.06%	106
2025 Q4	$630K	Buy	+260,259	New	+$597K	0.03%	102
2023 Q4	–	Sell	-101,918	Closed	-$493K	–	72
2023 Q3	$493K	Hold	101,918	–	–	0.04%	68
2023 Q2	$697K	Hold	101,918	–	–	0.06%	67
2023 Q1	$738K	Hold	101,918	–	–	0.05%	60
2022 Q4	$1.31M	Hold	101,918	–	–	0.11%	57
2022 Q3	$1.44M	Buy	101,918 +1,101	+1%	+$14.5K	0.12%	56
2022 Q2	$1.24M	Sell	100,817 -50,000	-33%	-$743K	0.09%	62
2022 Q1	$2.56M	Buy	+150,817	New	+$2.89M	0.2%	58

Other funds holding WHWK

Yu Fan $108M AUM 137.54% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

KCA

KVP Capital Advisors San Francisco, California $136M AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Eversept Partners's WHWK Position: Q2 2026 in Review

Eversept Partners reduced its Whitehawk Therapeutics (WHWK) stake by 1.1% in Q2 2026, selling an estimated $14.5K and leaving 303,306 shares worth $1.39M. The position accounts for 0.07% of the portfolio, ranked #99.

Eversept Partners first reported a position in WHWK in Q1 2022 and has held it in 10 quarters since. The position peaked at $2.56M in Q1 2022. 78 funds tracked by Wall St. Rank hold WHWK as of Q2 2026.

Eversept Partners held 303,306 shares of Whitehawk Therapeutics worth $1.39M as of Q2 2026.
Eversept Partners sold 3,494 Whitehawk Therapeutics shares in Q2 2026, an estimated $14.5K.
Whitehawk Therapeutics made up 0.07% of Eversept Partners's portfolio in Q2 2026, its #99 holding.
Eversept Partners first reported a position in Whitehawk Therapeutics in Q1 2022 and has held it in 10 quarters since.
Eversept Partners's Whitehawk Therapeutics position peaked at $2.56M in Q1 2022.
78 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q2 2026.

Based on Eversept Partners's 13F filing for Q2 2026, filed 14 Aug 2026.